Valuation : CSL Limited

Market Cap 59.21B 51.02B 47.84B 43.67B 82.26B 5,659B 82.53B 568B 221B 2,857B 222B 217B 9,472B P/E 2027 *
20.3x
P/E 2028 * 18.4x
Enterprise Value 68.1B 58.68B 55.02B 50.22B 94.61B 6,508B 94.91B 653B 255B 3,285B 256B 250B 10,893B EV / Sales 2027 *
4.33x
EV / Sales 2028 * 4.15x
Free-Float
99.97%
Yield 2027 *
2.44%
Yield 2028 * 2.58%
1 day-0.90%
1 week+2.39%
Current month+40.03%
1 month+44.18%
3 months+76.58%
6 months+17.42%
Current year-0.19%
1 week 168.4
Extreme 168.4
175.97
1 month 121.7
Extreme 121.7
175.97
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
8/21/26 Fiscal year

Director

152 0.0000%
8/21/26 Fiscal year

Director

244 0.0001%
8/21/26 Fiscal year

Director

-183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%+2.39%-18.98%-35.69% 59.21B
-1.67%-4.78%+37.02%-4.42% 79.3B
-3.35%-4.92%+463.91%+21.22% 55.09B
-6.78%-4.19%-4.50%+28.86% 49.86B
-2.43%-2.35%+8.03%+163.45% 47.9B
-1.35%+0.79%+64.72%-17.56% 32.28B
-2.64%-2.69%+48.59%+91.84% 25.21B
-0.09%+4.98%+18.59%+209.35% 23.87B
-0.34%+1.35%+60.10%+122.64% 16.89B
+2.73%0.00%-0.48%+845.45% 16.17B
Average -1.37%-1.09%+67.70%+142.51% 40.58B
Weighted average by Cap. -1.79%-1.97%+79.59%+75.06%

Financials

2027 *2028 *
Net sales 15.74B 13.56B 12.72B 11.61B 21.87B 1,504B 21.94B 151B 58.86B 759B 59.09B 57.81B 2,518B 16.28B 14.02B 13.15B 12B 22.61B 1,556B 22.68B 156B 60.87B 785B 61.11B 59.78B 2,604B
Net income 2.82B 2.43B 2.28B 2.08B 3.92B 269B 3.93B 27.01B 10.54B 136B 10.58B 10.35B 451B 3.16B 2.72B 2.55B 2.33B 4.38B 302B 4.4B 30.25B 11.8B 152B 11.85B 11.59B 505B
Net Debt 8.89B 7.66B 7.18B 6.55B 12.35B 849B 12.38B 85.17B 33.23B 429B 33.36B 32.64B 1,421B 8.39B 7.23B 6.78B 6.19B 11.66B 802B 11.7B 80.47B 31.4B 405B 31.52B 30.83B 1,343B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-08-28 A$172.32 -0.90% 1,158,131
26-08-27 A$173.88 +0.84% 874,276
26-08-26 A$172.44 -0.69% 1,014,011
26-08-25 A$173.64 +2.68% 1,212,519
26-08-24 A$169.11 +0.48% 1,138,160
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
123.63USD
Average target price
117.15USD
Spread / Average Target
-5.25%

Quarterly revenue - Rate of surprise